- A Strong International Strategy for Invisicare Is Put In Place
LAS VEGAS, Nov. 6 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI), the developers of Invisicare, a patented polymer delivery system that enhances topically applied products, today announced the appointment of Geert Cauwenbergh, PhD to head its International Advisory Board and to spear-head a focused strategy to expand the demand for Invisicare in international markets. Dr. Cauwenbergh has vast international experience in the dermatology market including research, development and the successful commercialization of pharmaceutical products with Barrier Therapeutics, Johnson and Johnson (NYSE: JNJ) and Janssen Pharmaceutica.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)
Dr. Cauwenbergh's career has been focused in dermatology. Early in his career he was the International Director of Clinical R&D, Dermatology and Infectious Diseases at the Janssen Research Foundation at Janssen Pharmaceutica in Belgium. This was followed with executive roles at Johnson & Johnson (J&J) including VP Research & Development for J&J Consumer Companies Worldwide, VP Product Development, as well as serving on the J&J Consumer Company's Management Board and Director of J&J' s Corporate Skin Care Council.
In 2001 he founded Barrier Therapeutics with offices in the US and
Belgium, raising over $250 million in venture capital as well as a listing
on the NASDAQ stock exchange. He developed a port
'/>"/>
| SOURCE Skinvisible, Inc. Copyright©2008 PR Newswire. All rights reserved |